Dr. Reddy’s Laboratories Limited (DRREDDY) is set to release its financial results for the quarter and six months ended September 30th, 2026 on Friday, October 23rd. The announcement will focus on key earnings and revenue insights. The company will hold an earnings call at 19:30 PM IST / 10:00 AM ET to discuss the financial performance. The call will be hosted by the company and can be accessed via the provided link for registration. This event marks a significant moment for investors and stakeholders to gain a deeper understanding of the company’s financial health and future prospects.

Financial Performance Overview

The upcoming release will provide detailed insights into Dr. Reddy’s Laboratories’ financial performance for Q2FY27. Notably, the company’s earnings and revenue are expected to reflect its strategic initiatives and market dynamics. The earnings call will offer a platform for management to elaborate on these aspects, highlighting key metrics and future growth strategies.

Investor Engagement

Investors are encouraged to participate in the earnings call to gain direct insights from the company’s leadership. The call will be available in audio format, with a transcript also accessible on the company’s website. This engagement is crucial for understanding the company’s current standing and future trajectory in the pharmaceutical sector.

As Dr. Reddy’s Laboratories Limited prepares to unveil its Q2FY27 results, the focus remains on delivering valuable financial insights that will guide stakeholders in making informed decisions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Dr. falls 10.4% over three months and has not found a floor yet. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 5.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -10.4% in three months on 11.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Dr. Reddy’s Laboratories Limited.

Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) today announced that the U.S. Food and Drug Administration (FDA) has approved its rituximab biosimilar, a biosimilar to Rituxan® (rituximab), for the U.S. market. This approval further strengthens Dr. Reddy’s growing global biosimilars portfolio and advances its biosimilars business in the United States. The product was developed, manufactured, and submitted for approval by Dr. Reddy’s Laboratories. The approval follows the successful recent Pre-License Inspection (PLI) conducted by the U.S. FDA at the Company’s biologics manufacturing facility in Bachupally, Hyderabad.

Strengthening Global Biosimilars Portfolio

The FDA approval is a significant milestone for Dr. Reddy’s Laboratories. The rituximab biosimilar has been commercialized in India, the European Union, the United Kingdom, and more than 25 emerging markets, and has also received marketing approval in Switzerland and Canada. This latest approval marks a major step in the company’s strategy to expand its biosimilars business in the U.S., one of the world’s most important pharmaceutical markets.

Commercialization Agreement with Fresenius Kabi

Under a commercialization agreement, Fresenius Kabi holds the exclusive rights to commercialize the product in the United States. This partnership will leverage Fresenius Kabi’s expertise and market reach to maximize the product’s availability and impact in the U.S. market.

As Dr. Reddy’s Laboratories continues to invest in its biosimilars business, this approval underscores the company’s capabilities in developing and manufacturing complex biologic medicines for global markets. The biosimilar is highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency, consistent with FDA requirements for biosimilar approval.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Dr. falls 13.2% over three months and has not found a floor yet. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. Revenue grows at 11.0% CAGR — a respectable pace. However, the stock drops 13.2% in three months without an obvious fundamental trigger. Sector-wide pressure or a valuation re-rating can persist for longer than expected. Therefore, there is no rush to step in. Check Fundamentals of Dr. Reddy’s Laboratories Limited.

Dr. Reddy’s Laboratories Limited (DRREDDY) fell -6% to ₹1266.7 on the NSE on 09 Jul 2026. The decline comes as the stock tested its 6M support trendline at ₹1267, bouncing from this key level. This move is notable as it follows a period where the stock had been hitting resistance levels, now shifting to support. In the broader healthcare sector, DRREDDY’s move appears to be more company-specific rather than a sector-wide trend.

Technical setup — trendlines & DMA

Currently, DRREDDY is navigating a critical technical juncture. The 6M support trendline is situated at ₹1267.26, just a whisker above today’s price, indicating a bounce from this support level. Resistance is noted at ₹1380.61, suggesting ample room for upward movement if the stock can sustain momentum. The 50-DMA at ₹1307.2 is above the 200-DMA at ₹1266.5, signaling a bullish trend. Despite today’s dip, the stock remains within the middle third of its 52W range, suggesting that much of the potential downside may already be priced in, while upside remains plausible.

Fundamentals & business context

With a PE of 26.5 and profit margins at 12.8%, DRREDDY’s valuation appears to be pricing in future growth rather than current earnings, especially given the revenue CAGR of 11.0%. However, the declining profit CAGR of -1.7% over the past five years raises questions about the sustainability of this growth. Institutional ownership stands at 52.5%, indicating a level of confidence among sophisticated investors, though the lack of a specific NSE catalyst today suggests that the move may be more technically driven. The negligible dividend yield of 0.59% and very low debt levels (D/E of 0.14) further frame the stock as a growth play rather than an income generator.

Algorithmic scorecard

The overall algorithmic scorecard reflects a technically strong but fundamentally weaker profile for DRREDDY. Two of the strongest signals are the bullish trend indicated by the 50-DMA being above the 200-DMA and the strong momentum across various timeframes, suggesting accelerating growth. Conversely, the declining profit CAGR and negligible dividend yield are significant weaknesses. The former indicates pressure on profitability, while the latter suggests limited income generation for investors, both of which could pose risks to long-term value creation.

Company outlook

Management’s forward guidance for DRREDDY is optimistic, with expectations for margins to improve and exceed 50% in FY27. The company plans to maintain SG&A spends at FY26 levels and increase R&D spends to 7-8% in the fiscal ahead. Key growth drivers include the launch of the oral version of semaglutide in India and expansion into more than 50 markets this calendar year, with plans to enter over 80 markets within 12 months. Management expects double-digit growth in North America excluding lenalidomide and biosimilar sales to reach US$ half a billion to 700 million by FY29, with abatacept as the major contributor. Capex for the next year is projected at ₹2,000 crores, focusing on biosimilars and specific product investments.

Get all details on DRREDDY — P&L, peers, shareholding and more on TradeAlone.